It appears that your browser may be outdated and performance may be limited. The My Study builder is best viewed with the latest internet browsers. However, if you’d prefer to use our standard form, you can access it below.

Go to Internet Explorer Quick Quote Form

Dismiss this message

Diagnostic Salivary Estriol ELISA Kit (CE Mark)

Technical Summary

Assay Protocol
Rev. 03.02.18
Specifications
Catalog#: 1-2812
Regulatory Status: CE Mark
Format: 96-well plate
Assay Time: ~ 24 hrs
Sample Volume/Test: 100 µL of X2 dilution
Sensitivity: 1 pg/mL
Assay Range: 5 pg/mL - 1215 pg/mL
Storage Requirements: 2-8°C
Tests Per Kit
Singlet: 76
Duplicate: 38
Target Analyte
Technical Documentation

References & Salivary Estriol Research

      1. Troisi, R., Potischman, N., Roberts, J.M., et al. (2003). Maternal serum oestrogen and androgen concentrations in preeclamptic and uncomplicated pregnancies.  Int J Epidemiol, 32(3), 455-60.
      2. Reis, F.M., D’Antona, D., Petraglia, F. (2002).  Predictive value of hormone measurements in maternal and fetal complications of pregnancy. Endocr Rev, 23(2), 230-57.
      3. Vining, R.F., McGinley, R., Rice, B.V. (1983). Saliva estriol measurements: An alternative to the assay of serum unconjugated estriol in assessing feto-placental function.  J Clin Endocrinol Metab, 56(3), 454-60.
      4. Kirkish, L.S., Compton, A.A., McCann, D.S. (1986). Salivary estriol as an index to fetal wellbeing.  Clin Chem, 32(1 Pt 1), 71-75.
      5. Heine, R.P., McGregor, J.A., Goodwin, T.M., et al. (2000). Serial salivary estriol to detect an increased risk of preterm birth. Obstet Gynecol, 96(4), 490-97.
      6. Weintrob, N., Drouin, J., Vallette-Kasic, S., et al. (2005).  Low estriol levels in the maternal triple-marker screen as a predictor of isolated adrenocorticotropic hormone deficiency caused by a new mutation in the TPIT gene.  Pediatrics, 117(2), e322-7.
      7. Canick, J.A., MacRae, A.R. (2005). Second trimester serum markers.  Semin Perinatol, 29(4), 203-8.
      8. Watson, C.S., Jeng, Y.-J., Kochukov, M.Y. (2008).  Nongenomic actions of estradiol compared with estrone and estriol in pituitary tumor cell signaling and proliferation. FASEB J, 22(9), 3328-36.
      9. Jacobson, H.I., Lemanski, N., Agarwal, A., et al. (2010). A proposed unified mechanism for the reduction of human breast cancer risk by the hormones of pregnancy.  Cancer Prev Res (Phil Pa), 3(2), 212-20.
      10. Larfors, G., Lambert, P.C., Lambe, M., et al. (2009).  Placental weight and breast cancer survival in young women.  Cancer Epid Biomark Prev, 18(3), 777-83.
      1. Hickey, M., Saunders, C., Partridge, A., et al. (2008). Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer.  Ann Oncol, 19(10), 1669-80.
      2. Mascarenhas, C., Lambe, M., Bellocco, R., et al. (2006). Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival.  Int J Cancer, 119(12), 2907-15.
      3. MacMahon, B. (2006).  Epidemiology and the causes of breast cancer.  Int J Cancer, 118(10), 2373-78.
      4. Lagiou, P., Samoli, E., Lagiou, A., et al. (2005).  Maternal height, pregnancy estriol and birth weight in reference to breast cancer risk in Boston and Shanghai.  Int J Cancer, 117(3), 494-98.
      5. Kassi, E., Moutsatsou, P. (2010). Estrogen receptor signaling and its relationship to cytokines in systemic lupus erythematosus.  J Biomed Biotech, 2010:317452.
      6. Ding, J., Zhu, B.T. (2007). Unique effect of the pregnancy hormone estriol on antigen-induced production of specific antibodies in female BALB/c mice.  Steroids, 73(3), 289-98.
      7. Rovenský, J. (2006).  Rheumatic diseases and Klinefelter’s syndrome: Review. Scripta Med (Brno), 79(4), 237-46.
      8. Sicotte, N.L., Liva, S.M., Klutch, R., et al. (2002).  Treatment of multiple sclerosis with the pregnancy hormone estriol.  Ann Neurol, 52(4), 421-28.
      9. Soldan, S.S., Alvarez-Retuerto, A.I., Sicotte, N.L., Voskuhl, R.R. (2003). Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol.  J Immunol, 171(11), 6267-74.
      10. Kika, G., Izumi, S.-I., Mori, A., et al. (2009).  Beneficial aspect of oral estriol as hormone replacement therapy: Consideration on bone and lipid metabolism.  Tokai J Exp Clin Med, 34(3), 92-98.
      11. Drača, S. (2006). Estriol and progesterone: A new role for sex hormones.  Int J Biomed Sci, 2(4), 305-7.
      12. Moutsatsou, V., Oakey, R.E. (1988).  Oestriol binding to plasma proteins.  J Steroid Biochem, 29(3), 319-23.
      13. Vining, R.F., McGinley, R.A., Symons, R.G. (1983).  Hormones in saliva: Mode of entry and consequent implications for clinical interpretation.  Clin Chem, 29(10), 1752-56.
      14. Evans, J.J., Wilkinson, A.R., Aickin, D.R. (1984).  Salivary estriol concentrations during normal pregnancies, and a comparison with plasma estriol.  Clin Chem, 30(1), 120-21.